PATENT CLAIM ANALYSIS

Application Number: 15769308
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "339000"]

Abstract:
The present invention provides a pharmaceutical composition for use in treating acute myeloid leukemia (AML) and a method of treating AML in a patient in need thereof. The present invention also provides a method for predicting the sensitivity to the treatment in the patient using gene expression signature.

Claim (Index 11):
A method of treating acute myeloid leukemia (AML) in a patient in need thereof, comprising administering to the patient an effective amount of (3\u2032R,4\u2032S,5\u2032R)\u2014N-[(3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl]-6\u2033-chloro-4\u2032-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2\u2033-oxo-1\u2033,2\u2033-dihydrodispiro[cyclohexane-1,2\u2032-pyrrolidine-3\u2032,3\u2033-indole]-5\u2032-carboxamide or a salt thereof.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.52941
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12438944', '13950881', '14560519', '14430635', '15566336']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7300038570207013
- 35 USC 102 Novelty (BERT): 0.5910017822564264
- Combined Prediction Score: 0.7161036495442737
- Mean Citation Score: 388.860316
- Max Citation Score: 521.67804
- Similarity Product: 411.6601480186701

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test